


Sino Biopharma banks on quality manufacturing

June 4, 2013 | Analysis | By BioSpectrum Bureau



13a-biospectrum-asia-top-20-survey-rank-13-sino-biopharmaceutical-china-profile

Sino Biopharmaceutical, an integrated name in R&D, manufacturing and marketing of health enhancing modernized Chinese medicines and chemical medicines, has continued to be a quality oriented enterprise in China. The group has strategically entered into healthcare and hospital business through the acquisition of Chia Tai Shaoyang Orthopedic Hospital.

Sino Biopharmaceutical manufactures therapeutic categories of cardio-cerebral diseases and hepatitis and develops medicines for treating tumors, analgesia, diabetes and respiratory system diseases.

During the year 2012, Sino Biopharmaceutical received 11 clinical approvals and four production approvals, completed clinical research of 57 cases for production approval, which included 10 cardio-cerebral medicines, 16 hepatitis medicines, 13 oncology medicines, four respiratory system medicines, one diabetic medicine and 14 other medicines, which are being developed.

Sino Biopharmaceutical is now looking into the development of genetic technology to improve the treatment and prevention of genetic diseases and stimulate the development of biopharmaceutical products. The company is seeking to cooperate with enterprises that possess advanced genetic technology and acquire intellectual proprietary technologies.

Strategically aiming at the international standard, the group's jointly-controlled entity, Beijing Tide Pharmaceutical has received GMP certification for foreign pharmaceutical company from the Public Welfare and Health Ministry of Japan, thus opening window for Japanese pharmaceutical enterprises to invest in the company. The company has also established the Post-Doctoral R&D Institute, the only new hepatitis medicine research center in the country.

Sino Biopharmaceutical's major product, Kaishi injections, which is produced by Beijing Tide works, is the first micro-sphere target sustained release medicine in China to improve cardio-cerebral microcirculation blockage.

Sino Biopharmaceutical's Tianqingning injections, a plasma-volume expander for patients with blood volume deficiencies, have shown strong performance in the market and its medicine for hepatitis B, Runzhong (Entecavir) dispersible tablet, has obtained a product approval certificate and production approval.

Runzhong dispersible tablet is the latest generation of guanine nucleoside analogue oral medicine used mainly for the treatment of hepatitis B. It inhibits viral replication and has lower risk of triggering the emergence of medicine-resistant virus.